Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 31, 2026Open Access

Contemporary evidence supports individualized and risk-stratified use of MHT, particularly in symptomatic women younger than 60 years or within 10 years of menopause onset.

View Full Paper
Ask AI
Bookmark
Share

Population

Postmenopausal women

Design

Review

Authors

DKDr. Virendra Kushwaha*

Discussion

Loading...

Member takes

Overview

May warrant individualized MHT assessment; leaves open dedicated trials for neurokinin antagonists.

Key Points

  • This research aims to explore the multifactorial pathophysiology and novel treatment approaches for postmenopausal hypertension.
  • Review of molecular mechanisms involved in postmenopausal hypertension
  • Assessment of menopausal hormone therapy (MHT) effectiveness
  • Evaluation of emerging treatments including neurokinin receptor antagonists and phytoestrogens.
  • Identified key factors like oxidative stress and endothelial dysfunction contributing to hypertension in postmenopausal women.
  • MHT offers benefits but requires careful consideration of individual cardiovascular risk profiles and timing.
  • Emerging therapies, such as neurokinin receptor antagonists, show promise for managing vasomotor symptoms.

Structured PICO

P
Population
Postmenopausal women
I
Intervention
Menopausal hormone therapy (MHT) and novel non-hormonal therapies (e.g., neurokinin receptor antagonists)

This review highlights the multifactorial pathophysiology of postmenopausal hypertension and supports individualized use of menopausal hormone therapy alongside emerging non-hormonal treatments.

Cite This Study

Dr. Virendra Kushwaha* (2026) studied this question.

synapsesocial.com/papers/6a1bd2845783ba022b6fe00chttps://doi.org/10.5281/zenodo.20444073
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mechanisms of Hypertension in Women: Interactions Between Vascular Ageing, Metabolic Dysfunction, and Hormonal Regulation2026
  2. 2Cardiovascular Risk Associated with Menopause and Menopause Hormone Therapy: A Review and Contemporary Approach to Risk Assessment2025
  3. 3Cardiovascular Health During Menopause Transition: The Role of Traditional and Nontraditional Risk Factors2025
  4. 4Metabolic syndrome in menopause2025 · 6 citations
  5. 5From sex hormone decrease to hormonal treatment: impacts on cardiovascular risk with ageing.2025